0001193125-26-219641
SEC filingQ1 2026 operating loss widened 22.2% to -$17.8M as R&D increased on PAH program costs, driving net loss to -$16.4M and free cash burn to -$12.1M despite EPS improvement to -$0.10.
Inhibikase Therapeutics reported a GAAP operating loss of -$17.8 million for Q1 2026, representing a 22.2% year-over-year widening from -$14.6 million. This deterioration stems from elevated research and development expenses, where increases were primarily driven by PAH program costs following the absence of a prior-period charge. These costs remain a significant component of R&D, underscoring the company's focus on advancing its lead pulmonary arterial hypertension candidate through clinical stages.
Net income followed suit at -$16.4 million, a 19.8% worsening from -$13.7 million in the prior year, with diluted EPS improving to -$0.10 from -$0.15—a 33.3% betterment on a per-share basis. This EPS dynamic highlights share count effects amid persistent losses.
Cash flow from operations consumed -$12.1 million, equating to free cash flow given zero capital expenditures, compared to -$4.1 million last year. The acceleration in burn aligns with compensation and program-driven expense growth, positioning liquidity as a key watch item. Historically funded through grants and contracts pre-IPO, the company notes potential needs for additional capital as operating plans evolve and clinical milestones approach.